Effects of beta-hydroxybutyrate administration on MK-801-induced schizophrenia-like behaviour in mice.

Abstract

Impaired cerebral glucose metabolism is a core pathological feature of schizophrenia. We recently demonstrated that a ketogenic diet, causing a shift from glycolysis to ketosis, normalized schizophrenia-like behaviours in an acute N-methyl-D-aspartate (NMDA) receptor antagonist model of the illness. Ketogenic diet produces the ketone body, β-hydroxybutyrate (BHB), which may serve as an alternative fuel source in its own right without a strict dietary regime. We hypothesized that chronic administration of BHB replicates the therapeutic effects of ketogenic diet in an acute NMDA receptor hypofunction model of schizophrenia in mice. C57Bl/6 mice were either treated with acute doses of 2mmol/kg, 10mmol/kg, or 20mmol/kg BHB or received daily intraperitoneal injections of 2mmol/kg BHB or saline for 3weeks. Behavioural testing assessed the effect of acute challenge with 0.2mg/kg MK-801 or saline on open field behaviour, social interaction, and prepulse inhibition of startle (PPI). Acute BHB administration dose-dependently increased BHB plasma levels, whereas the 2mmol/kg dose increased plasma glucose levels. The highest acute dose of BHB supressed spontaneous locomotor activity, MK-801-induced locomotor hyperactivity and MK-801-induced disruption of PPI. Chronic BHB treatment normalized MK-801-induced hyperlocomotion, reduction of sociability, and disruption of PPI. In conclusion, BHB may present a novel treatment option for patients with schizophrenia by providing an alternative fuel source to normalize impaired glucose metabolism in the brain.